Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABT-925
- Development stage
- Discontinued
- Lead developer
- Abbott
- Modality
- Small Molecules
01
Overview
ABT-925 is a selective dopamine D3 receptor antagonist developed by Abbott Laboratories for the treatment of schizophrenia. It exhibits approximately 100-fold higher in vitro affinity for the dopamine D3 receptor compared to the D2 receptor. As a small molecule antipsychotic in the piperazine and pyrimidine chemical classes, it was evaluated in phase II clinical trials for schizophrenia but did not demonstrate significant efficacy over placebo and was generally well tolerated. Development of ABT-925 was discontinued in December 2007[1][3][4].
- Other names
- ABT-925 anhydrous free baseABT925 anhydrous free baseABT 925 anhydrous free base
02
Targets
DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)
Beyond the preview
Go deeper on ABT-925.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABT-925.